Remove 2020 Remove Competition Remove Prescription
article thumbnail

PBMs and insurers want your prescription money

World of DTC Marketing

For many, these coupons represent the difference between filling a prescription and going without lifesaving care, but there is a lot more here than just a co-pay coupon. Those health insurers, in turn, use the discounts to offer more competitive premiums in a bid to attract enrollees. These pricing scams hurt patients as well.

Insurance 226
article thumbnail

Pharma’s reputational high will be short-lived

World of DTC Marketing

Pharma has gone to court again and again to delay generic competition of biologic drugs. One company AbbVie has used the courts to stop competition of its top drug Humira. By the look of 2020’s results, he’s on the right track—and his compensation shows it. For writing that 2020 success story, CEO Albert Bourla, Ph.D.,

Pharma 186
article thumbnail

Pharma is “big business” that uses excuses to keep prices high

World of DTC Marketing

Seventy-nine percent of Americans think the price of prescription drugs is “unreasonable,” according to a 2019 Kaiser Family Foundation poll , and about 9 in 10 say they support the idea of the government negotiating prices. For 17 of the 20 top-selling drugs worldwide in 2020, pharmaceutical corporations made more money from U.S.

Pharma 241
article thumbnail

UnitedHealth-Walmart partnership heats up U.S. Medicare provider competition

Clarivate

Insurers that incentivize using Walmart facilities in Medicare Advantage and prescription drug plans (PDPs) have seen success; Humana has a long-running standalone Part D plan with Walmart pharmacies as preferred network locations. Medicare provider competition appeared first on Clarivate. payer marketplace, please visit us here.

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

1 For use as prescription drugs, a botanical product must be approved by the FDA: to date, only two have gained this approval. The MA pathway is applicable for herbal medicines designed to treat more serious health conditions and require a medical prescription or the supervision of a medical practitioner. 2012/1916).

Marketing 103
article thumbnail

Nine for 2023, part three: thriving or surviving?

pharmaphorum

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.

article thumbnail

Nine for 2023, part one: a reflection on inflection

pharmaphorum

Some of the more resilient launches since 2020 have had these benefits to health systems. The innovative prescription medicine industry faces a trifecta of challenges. Now, for major specialty care therapy areas, including Hepatis C, Immuno-oncology and HIV, there is a competitive launch nearly every year. Pharma boxed in?